Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Venture Financing 16
Syngene May Raise Over USD50 Million in Venture Financing 16
Private Equity 17
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Partnerships 22
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Licensing Agreements 34
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Equity Offering 42
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Asset Transactions 45
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd – Key Competitors 46
Biocon Ltd – Key Employees 47
Biocon Ltd – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Joint Venture 48
Recent Developments 50
Strategy And Business Planning 50
Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia 50
Financial Announcements 51
Oct 25, 2018: Biocon announces financial results for the second quarter ended on September 30th, 2018 51
Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 54
Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd] 57
Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 60
Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore 63
Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 67
Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 70
Legal and Regulatory 73
Sep 22, 2018: Biocon’s drug substance facility in bangalore completes US FDA inspection with No observations 73
Jul 04, 2018: Biocon’s Sterile Drug Product facility Receives EU GMP Certification 74
Jun 23, 2018: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA 75
May 02, 2018: Biocon Regulatory Audit Update 76
Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 77
Feb 21, 2018: Biocon Announces US-FDA Inspection at Malaysian Manufacturing Facility 78
Nov 20, 2017: Biocon’s Drug product Facility Receives EIR with VAI status, Inspection Closed 79
Sep 18, 2017: Biocon’s Facility in Vishakhapatnam completes USFDA Inspection with no observations 80
Jul 09, 2017: Biocon provides update on Bangalore Facility 81
Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 82
May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 83
Other Significant Developments 84
Dec 13, 2017: Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee” 84
Oct 06, 2017: Biocon: No Separate Audit or Observations by Health Canada 85
May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87
Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Syngene May Raise Over USD50 Million in Venture Financing 16
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd, Key Competitors 46
Biocon Ltd, Key Employees 47
Biocon Ltd, Subsidiaries 48
Biocon Ltd, Joint Venture 48
List of Figures
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
【免責事項】
http://www.globalresearch.jp/disclaimer